Bridgebio Pharma Says Intends To Initiate Registrational Clinical Study Of Encaleret In 2026
ReutersSep 6, 2025 6:32 PM
Sept 6 (Reuters) - BridgeBio Pharma Inc BBIO.O:
BRIDGEBIO PHARMA - INTENDS TO INITIATE REGISTRATIONAL CLINICAL STUDY OF ENCALERET IN 2026
ENCALERET WAS WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS REPORTED OVER STUDY PERIOD
PHASE 2 STUDY EVALUATED ENCALERET'S EFFECTS ON CALCIUM HANDLING
Further company coverage: BBIO.O
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Broadcom Q3 FY2025 Earnings Review: AI Surge and VMware Synergy Fuel Record Performance
TradingKey - Broadcom Inc. (NASDAQ: AVGO) delivered a strong fiscal Q3 2025, with results driven by AI networking strength and continued VMware integration. Revenue and EPS both topped expectations, reinforcing the company’s role as an essential player in the AI infrastructure buildout.TradingKey
Fri, Sep 5
U.S. August Nonfarm Payroll Preview: Risks Focus on Downward Revision of July Data
TradingKey - On 5 September 2025, the U.S. Department of Labour will release the August Non-Farm Payrolls report. The market widely expects August to see an addition of 75,000 non-farm jobs, roughly in line with July’s 73,000.TradingKey
Thu, Sep 4
Unlocking Gold’s Next Leg: $4,000 in Reach by 2025？
TradingKey - Gold has kicked off a fresh uptrend in early September, breaking out of months of compression and reclaiming key territory. The decisive move above $3,500 establishes a new support base and puts higher objectives back on the table for the weeks aheadTradingKey
Thu, Sep 4
US NFP Nightmares Preview: A Tiny August Revision, a Huge Annual Benchmark Cut And a Fed in Flux
TradingKey - Wall Street expects modest job growth and a rebound in the unemployment rate in August NFP report, a balanced outcome that could support a September rate cut. However, a massive downward revision — a “terrifying scene” — and anomalies on the supply side could plunge the Fed into deeperTradingKey
Wed, Sep 3
 (1).jpg)
2025 Hottest US IPO Week: Klarna, Gemini, Figure Set for “Triple Launch”
TradingKey - 5 companies are now pricing their U.S. initial public offerings (IPOs) for the week starting September 8, with a total expected fundraising exceeding $3 billion, making it the busiest IPO week of 2025. Investors are closely watching the debut performance of Klarna, Gemini, and Figure.TradingKey
Wed, Sep 3
Tradingkey
